MedTrace Logo

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

NCT07046221 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-20

No results posted yet for this study

Summary

To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group

Conditions

  • Esophagus Cancer

Interventions

DRUG

Tislelizumab

200mg，d1，q3w，1years

DRUG

Albumin-Bound Paclitaxel

125mg/m2，d1，d8，q3w，2cycles

DRUG

cis-platinum

75mg/m2，d1，q3w，2cycles

PROCEDURE

Surgery

Radical resection of esophageal cancer

RADIATION

Radiation

50.5Gy/28f

DRUG

Nedaplatin

80-100mg/m2，d1，q3w，2cycles

DRUG

Carboplatin

AUC=5，d1，q3w，2cycles

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2027-08-01
Completion
2030-08-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07046221 on ClinicalTrials.gov